Rafaèle Tordjman

Fitting that my first ever post is about…v@ginas?! This is sufficiently important that I felt compelled to reshare Seed Health’s launch of a truly milestone product for women’s health. There’s simply nothing like VS-01 in the world. In fact, the world’s first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome. More than 2/3 of women report experiencing vaginal discomfort annually —> More than 1.75 billion women globally over the age of 20. ~90% of women lack a stable vaginal microbiome according to Jacques Ravel’s pioneering research elucidating the crucial role of the vaginal microbiome in gynecological, urogenital, and reproductive health. 1.75 billion experiencing discomfort, yet literally *zero* products clinically shown to help. UNTIL NOW. Definitionally groundbreaking. Congrats Seed Health!

30

1 commentaire

Introducing the Game-Changing MRI Iseult 🚀 I want to share an advancement that will have a major impact on our understanding of psychiatric and neurodegenerative diseases: the MRI Iseult. 🕰 After two decades of tireless research, the French CEA laboratory has unveiled a state-of-the-art device with an unprecedented resolution of 11.7 teslas. It is three times more precise than standard models. To view the article click here 👉 https://lnkd.in/ewv-PGWP 🧬This achievement heralds a new era in neurology and medical R&D, promising advances in deciphering the complexities of the human brain. Thanks to its unrivaled precision, visionary entrepreneurs will translate their aspirations into tangible advances in understanding the brain. The Iseult MRI holds the key to understanding diseases such as Alzheimer's, Parkinson's and psychiatric disorders. This MRI will also improve our knowledge of the role of lithium in the treatment of schizophrenia and bipolar disorder. This innovation will enable startups to develop new products and services. This is precisely the idea behind Newfund’s latest initiative, Heka, a VC fund dedicated to supporting startups leveraging biological data linked to the brain to enhance our health. In this particular domain, so important for us as individuals and for our species since the brain plays such a role for Sapiens, there is no innovation without a deep understanding of the latest scientific discoveries. Tools such as Iseult are a major help for this endeavor. Newfund is humbled to be part of this adventure, in its modest place. cc Marion Leboyer, Veronique Briquet-Laugier, Michael Jackson, Anne-Sophie Saint-Martin, Constant Beroulle #Heka #MRI #BrainHealth #deeptech #Innovation #Research #Neurology #Breakthrough

33

🌟 Europe! It’s time to boldly build together to create a better and brighter system of care. 🌟 It was energizing for Alexandre Momeni and myself to meet with so many talented entrepreneurs and leaders across pharma, payers, providers and policy at HLTH Europe, all committed to making a difference in European healthcare. Here are a few of takeaways: ✅ An ambitious new generation of European digital health innovators is emerging. Following in the footsteps of Sword Health, Alan and Doctolib, companies like Doccla, Nabla, Corti and Causaly are pioneering world-class solutions to bridge the critical gaps in Europe’s healthcare infrastructure. They are creating a future instead of optimizing the present and their success will raise the bar, attracting more talent and investment in the space. ✅ Our academic health systems are undergoing a ‘renAIssance’. Lighthouse health systems like Sheba Medical Center, Tel Hashomer, Charité - Universitätsmedizin Berlin, Guy's and St Thomas'​ NHS Foundation Trust and Greater Paris University Hospitals - AP-HP are re-imagining their business models to shift care out of the hospital, making strategic investments and embracing innovative solutions to leapfrog their most pressing challenges, including with (Gen)AI. AI is not just a tool for efficiency; it’s a catalyst for more effective healthcare. ✅ Radical collaboration is the path to success. HLTH, with over 3,500 attendees from over 60 countries convening in Amsterdam, is proof that when we are bold and join together as a community, bringing the best minds and hearts together to engage and share ideas, we make progress. This is critical in Europe where the geographic and regulatory complexities of the market means greater coordination and intentionality is needed to achieve real system-level change instead of diffuse pockets of innovation. As an investor in European digital health for over a decade, I’m excited by how vibrant the ecosystem is becoming. At General Catalyst, we are committed to creating, investing, partnering and operating to enhance the resilience of European healthcare — all in the pursuit of Health Assurance. Let’s seize this moment!

131

2 commentaires

Nephrolytics: Transforming Kidney Disease care with Vision and Determination “The real difference between success and failure in a corporation can very often be traced to the question of how well the organization brings out the great energies and talents of its people… I believe that any organization, in order to survive and achieve success, must have a sound set of beliefs on which it premises all its policies and actions.” - Thomas Watson Jr. “A Business and Its Beliefs,” At Nephrolytics, we embrace this wisdom wholeheartedly. Our core belief is centered around transforming healthcare from a system burdened by the volume of disease to one that truly values the health of people. This mission propels every aspect of our work, from product development to strategic partnerships, echoing Watson’s conviction. Our journey is akin to that of Dr. Ignaz Semmelweis in 1847, who faced immense challenges in shifting medical practices to save lives. Despite the success of his infection control procedures, Semmelweis’s ideas were met with resistance and significant challenges. Similarly, Nephrolytics is dedicated to a path that is not easy but is undeniably crucial. We address the urgent need for systemic change—reducing physician burnout through more efficient systems and better data integration, and preparing for an impending physician shortage, particularly in nephrology. Our AI-driven platform functions as an EMR-agnostic stand-alone workflow station for providers, designed not only to enhance the quality of care but also to reduce cognitive burden & operational costs. It supports healthcare professionals in their mission to deliver exceptional care without undue strain. As we continue our journey, we seek more individuals to join us—those who resonate with our vision. We offer our advisors, investors and strategic partners not just an investment opportunity but a chance to share in a vision that transcends monetary contributions. This collaboration is about a shared mission and collective effort. Thomas Watson Jr. wisely stated that the enduring success of a corporation relies not just on its ability to adapt technologies or strategies but “fundamentally on how it cultivates and utilizes the energies and talents of its people.” He believed in the strength of an organization rooted in clear and firm beliefs, guiding all actions and decisions. This philosophy highlights the importance of fostering a unified purpose that deeply connects with everyone involved, ensuring resilience and continued relevance through changes and challenges. That is what I believe we are harnessing at Nephrolytics. Together, we are not merely participants in healthcare reform but are actively driving its evolution. Tina Gill Adam Haid Naeem Rahim Ali Nadeem Mian Ali Tyler Cady Hasan Ayub Brian Mason Matthew Brooks Yasir Lashari Kartik Sharma 🙌🏾 #Healthcare

65

6 commentaires

Over the past few days, I’ve been visiting lots of #farms in Europe and seeing the #regeneration and #destruction that management practices can have in the #land, #nature and environment. These practices are relatively unknown to the consumer and the huge gap between regenerative practices and industrial agriculture as well as the #positiveimpact that regenerative management can have! How do we create #impact in food systems? It starts with the health of farms #soils. Lots of positive externalities come from restoring soils. Soil health is an #outcome and regenerative practices have to be outcome driven. I’ll be talking about creating ‘impact in food systems and regenerative agriculture’ at the Impact Investor Global Summit in London Tuesday next week alongside fellow panelist’s Rosie Wardle, Carli Roth, Matteo Squilloni and Charles Avery. With lots more discussion about regenerative agriculture, sustainable farming and organic conversions - it’s an excellent time for this panel which touches on #naturalcapital, #farming and #foodsystems. Especially in the wake of the latest season of Clarksons Farm where #AndyCato and George Lamb with Wildfarmed joined #JeremyClarkson and Charles Ireland on the farm. Maybe Regenerate Outcomes will be there next season 😉 Our team at Regenerate work across Private Equity, Outcomes and Venture Capital, all working across regenerative agriculture. Come and see us at the event! Regenerate Asset Management European Investment Fund (EIF) Synthesis Capital The Rockefeller Foundation New Private Markets Ryan Cameron David Bates Nicholas Burlington Addy Windsor-Clive Erik Bruun Bindslev Oliver Martin Jeremy Stroud Timothy Coates Taimur Malik Philippa Saxon Matt Jordon Tom Dillon Christopher Heathcote Jake McNaughton

60

1 commentaire

Space tech-focused investment firm Seraphim Space Space launched its second VC fund, SSV II, to back early-stage startups in the global space tech market. The fund aims to build a portfolio of 30 startups, investing in seed and Series A stages. The latest fund's target size is larger than its predecessor's, which closed at £70M ($90M) in 2017. The fund's investment themes include AI applications for space data, in-orbit computing, space-enabled communications, and microgravity for science. Eutelsat is one of the limited partners that contributed to the latest fund. Seraphim Space aims to stand out with its track record, having returned three times the original investment from its first fund. The first fund's returns were driven by five exits, including Siemens' acquisition of UltraSOC and four IPOs of Arqit, AST SpaceMobile, Nightingale, and Spire Global. The British firm listed its growth fund Seraphim Space Investment Trust (SSIT) on the London Stock Exchange in July 2021, getting about £250M (~$300M) in gross proceeds. The fund's market cap touched an all-time low of £130M ($162M) in July 2023. The market for space tech is expected to grow significantly, with the World Economic Forum and McKinsey estimating it could be worth $1.8R by 2035.

8

1 commentaire

The last few days I've been attending SynBioBeta conference in San Jose, CA. Really cool innovations that are tackling big problems in health, industrial production, and climate. It was also AgFunder's AGM... some non-standard observations: 1- Venture markets are not back: it will not be a bounce, but a slow recovery 2- Smart startups are partnering with engineering/EPC firms earlier in their life. This is key to de-risk scale production from day 1. My first employer out of college Black & Veatch was a key partner in the growth of Tesla, and now they're active in the bio space 3- If you say you're AI, you better prove it. Nothing wrong with saying you're doing ML

15

🚀 Biggest Startup Funding Rounds Last Week🚀 #1: Metsera 💼 Sector: Biotech 💰 Funding: $290M 📝 Details: New York-based Metsera emerged from stealth mode with a whopping $290 million funding round led by Arch Venture Partners. Specializing in medicines for obesity and metabolic diseases, Metsera offers a range of oral and injectable therapies. #2: Rivos Inc. 💼 Sector: Semiconductor 💰 Funding: $250M 📝 Details: Santa Clara's Rivos secured over $250 million in a Series A-3 funding round, spearheaded by Matrix Capital Management. Their expertise lies in power-optimized chips tailored for data analytics and generative AI markets. #3: Ramp 💼 Sector: Fintech 💰 Funding: $150M 📝 Details: New York-based Ramp raised $150 million in their latest funding round led by Khosla Ventures and Founders Fund. With a valuation spike to $7.65 billion, Ramp focuses on streamlining corporate card and expense automation solutions. #4: Two Chairs 💼 Sector: Healthcare 💰 Funding: $72M 📝 Details: San Francisco's Two Chairs closed a $72 million Series C round, enhancing their behavioral health platform. Utilizing a proprietary algorithm, they match patients with suitable therapists, boasting a team of over 500 clinicians. #5: Cape 💼 Sector: Mobile 💰 Funding: $61M 📝 Details: Arlington-based Cape raised $61 million in their debut round led by A* and Andreessen Horowitz. Their focus on developing a privacy-first mobile network addresses prevalent security concerns in the telecom industry. #6: Avive Solutions Inc. 💼 Sector: Healthcare 💰 Funding: $57M 📝 Details: SF's Avive Solutions secured $56.5 million in growth equity financing led by Catalyst Health Ventures, Laerdal Million Lives Fund, and Questa Capital Management. They specialize in connected automated external defibrillators. #7: Asher Biotherapeutics 💼 Sector: Biotech 💰 Funding: $55M 📝 Details: South San Francisco's Asher Biotherapeutics closed a $55 million Series C round led by RA Capital Management. Their focus on targeted immunotherapies for various diseases shows promising potential. #8: Corner Therapeutics 💼 Sector: Biotech 💰 Funding: $54M 📝 Details: Watertown's Corner Therapeutics raised $54 million in funding led by Ziff Capital Partners. Specializing in immunotherapy, they're dedicated to developing innovative treatments. #9: Kontakt.io 💼 Sector: Artificial Intelligence 💰 Funding: $48M 📝 Details: New York-based Kontakt raised $47.5 million in funding led by Goldman Sachs Asset Management. They provide health systems with analytics on staff and patient movement within facilities. #10: Anvilogic 💼 Sector: Cybersecurity 💰 Funding: $45M 📝 Details: Palo Alto's Anvilogic closed a $45 million Series C round led by Evolution Equity Partners. Focusing on security information and event management, they strive to protect organizations from cyber threats. #startups #funding #startupfunding ---- Subscribe to my newsletter: newsletter.foundersbay.com

49

8 commentaires

🎉 Venture Catalysts Leads $500k Pre-Seed Funding in Robotics Firm Perceptyne ! Venture Catalysts is proud to lead a pre-seed funding round in Perceptyne, an innovative deeptech AI & Robotics startup founded by the brilliant minds of Raviteja Chivukula, Jagga Raju N., and Mrutyunjaya Nadiminti, alumni of esteemed institutions like IIT and BITS. Joining us in this journey are industry stalwarts like Tarun Mehta and Swapnil Jain from Athera Venture Partners (formerly Inventus India), along with Pawan Kumar Chandana and Bharat Daka from Skyroot Aerospace. The support from T-Hub, z21 Ventures, and individual founders like Naveen, Satya, and Aditya Damani further validates the potential of Perceptyne's groundbreaking vision. Perceptyne is set to disrupt the industrial automation landscape with India's first Industrial Humanoid Robots, ushering in a new era of efficiency and productivity on the factory floor. With the global and Indian automation market poised for exponential growth, Perceptyne's innovation couldn't have come at a better time. At Venture Catalysts, we're committed to nurturing disruptive technologies, and our investment in Perceptyne is a testament to that. We're excited to see the team Perceptyne scale new heights and redefine the future of robotics. Venture Catalysts++ | India's 1st Multi-Stage VC, 9Unicorns, Anuj Golecha, Anil G Jain, Gaurav Jain, Vansh Oberoi, Shruti Arya, Anvit Baliga, Madhav Bhaskar, Sei Deshpande #VentureCatalysts #AngelInvestor #VC #IndianStartups #VentureCapital #DeepTech #Innovation https://lnkd.in/deWt5pg8

98

2 commentaires

Taking a regenerative approach to business/leadership is not a "checkbox" activity. How you "get there" and what it "looks like" is unique depending on the company. In fact, the exercise of enforcing a standard checklist of activities that must be completed to be regenerative is NOT regenerative in itself. The article Cordell Jacks refers to below is brilliant - it really describes the desired approach we are trying to model at Regenerative Capital Group.

7

𝐓𝐈𝐌𝐄𝟏𝟎𝟎𝐇𝐞𝐚𝐥𝐭𝐡'𝐬 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬 𝐚𝐧𝐝 𝐥𝐞𝐚𝐝𝐞𝐫𝐬 🌟 TIME has once again spotlighted the extraordinary individuals steering global health towards new frontiers. They've categorized these leaders as: 1️⃣ Innovators: Crafting cutting-edge, transformative medical technologies. 2️⃣ Titans: Powerhouses defining the industry standards. 3️⃣ Pioneers: Venturing into unexplored territories in healthcare. 4️⃣ Leaders: Strategizing and executing impactful healthcare policies. 5️⃣ Catalysts: Igniting rapid advancements and inspiring global movements. Each role is pivotal, each person a beacon of potential. Their stories inspire us to think bigger and push harder in our pursuits. Who among these titans inspires you the most? https://lnkd.in/d4kGgdPT #TIME #Leadership #Innovation #Healthcare #

15

5 commentaires

Advice from today's esteemed panel on accessing #healthcare #investment. "It's never too early to build your network with investors. Socialize your ideas to help sharpen your thesis. You can never underestimate the value of early feedback." Rami Hannoush, Ph.D. "Surround yourself with an advisory board that actually helps. They should be working on your behalf to help you access THEIR networks." Jennifer Friel Goldstein "Build your network early and pressure test your story with advisors." Nate Chang "Get to Silicon Valley early and often, and leverage programs like #ValleyReady that CELS - Canadian Entrepreneurs in Life Science offers because it can be game changing for your business." Cedric Bisson

42

7 commentaires

Insights from this article shed light on successful strategies for MedTech startups. Critical factors include prioritizing user-friendliness, ensuring robust data security, and seamless integration with existing systems. Navigating market differences between Europe and the US is crucial, with distinct financing systems and regulatory landscapes shaping global expansion strategies. #MedTech #StartupStrategies #Innovation  

1

🌟 Functional precision medicine, a leap forward for cancer therapy. 🔬 A recent study suggests that ex vivo drug screening of pediatric cancer samples could revolutionize treatment options. If validated, this approach could be transformative for young patients. See the link to the article by De La Rocha et al, Nat Med 30 (2024) in comments section. #PediatricCancer #PrecisionMedicine American Association for Precision Medicine (AAPM) #aapmhealth #aapm_health #MedicalResearch 🎗️🔬

4

1 commentaire

🔬 The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor's perspective in this space can help founders prepare more effectively for their fundraise. Investment Manager, Dr Marina Fuentes, details the most critical aspects Mercia Ventures and other investors look for at the Series A stage. Read more ⏬ #BioManufacturing #Blog #Investor #VentureCapital #Investment #SeriesA #Founders #Opportunity #Learning

5

New week, new CVC! Huge congrats to Eric Truebenbach for launching Teradyne Robotics Ventures, and a big kudos to my colleagues Patrick FitzGerald and Danny Boisson for being part of the journey. It's so encouraging to see more and more investors understand the importance of hardtech and robotics, and it's not every day that a new CVC launches and shows their commitment by making an investment in the first two weeks! As always, for my VC friends, if you have portfolio companies in the robotics space looking to bring on strategic capital from one of the world's giants in automation, let us know! If you are a passionate entrepreneur working on hardware or software solutions within robotics, please reach out! We'd love to talk to you. #venturecapital #startups #robotics #hardware #corporate #cvc #corporateventurecapital

117

10 commentaires

Prepping for Formula 1's #Monaco #GP and this title fits in nicely. Venture Capital essentials as moderated superbly by Ken Nelson with participation from Gregory Madden, Linus Rieder, Julien L. Pham, MD, MPH, Bhavesh Barot, Sanchita Pasi, Enric Claverol. Read below 👇 if you've got some more time on your hands, watch full panel here, which was intelligently curated by Giovanni Lauricella & Lifeblood, who are also joining us in full force this year. 🚀

38

1 commentaire

3 noteworthy acquisitions were announced in #DigitalHealth last week, moving the total to 76 acquisitions in 2024 till date. - On Tuesday, Switzerland-based Mediktor announced the acquisition of Sensely, a San Francisco-based digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. - On Thursday, Carevīve was acquired by Health Catalyst. The acquisition strengthens Health Catalyst's position in the digital healthcare market, expanding its capabilities in patient engagement and care coordination. - On Friday, Doktor.se announced that it acquired competitor Doktor24. The combined entity will provide a comprehensive suite of digital healthcare services, including telemedicine consultations, patient engagement platforms, and data analytics capabilities. Compared to last year, the total number of acquisitions is still trending significantly lower. Till date, the M&A activity in Digital Health has been 14% lower as compared to the same period last year. #Merger #Acquisitions #healthcarefinancing Source: All data from Alpha Edge, the business intelligence tool in HealthTech Alpha

18

1 commentaire

Excited to share insights from our recent panel discussion on the latest trends in biotech and healthcare investments. We touched upon the following topics: 💡 Investment Trends in Biotech and Healthcare: Opportunities include continued innovation, and emerging technologies. 🧬 Advancements in Longevity and Regenerative Medicine: Breakthroughs in senescent cell clearance, stem cell rejuvenation, telomere biology, and the Klotho protein hold promise for extending healthspan and lifespan. 👵 Ethical Implications of Extending Human Lifespan: Equitable access, overpopulation, cultural impacts, generational conflict, and autonomy are key dilemmas. Inclusive governance and public dialogue are crucial for responsible navigation. 🤖 AI and Precision Medicine: AI is transforming personalized healthcare by integrating multi-omic data, enhancing biomarker discovery, predictive modeling, and clinical decision support, paving the way for more tailored and efficient treatments. ✂️ Gene Editing and CRISPR Technology: Ethical considerations include safety, access, human enhancement, and consent. Regulatory frameworks must evolve to ensure robust governance, public engagement, and global coordination. 🏥 Decentralized Clinical Trials and Remote Monitoring: DCTs increase patient access and retention, collect real-world data, and save costs, but face challenges in data quality, regulatory compliance, and technology infrastructure. Remote monitoring enhances patient engagement and data integrity. 📱 Health Tech and Wearable Devices: Wearables enable remote monitoring and personalized care but face barriers like data privacy, accuracy, user experience, integration, cost, and regulatory oversight. 🚀 Regulatory Pathways for Innovative Therapies: Biotech companies navigate complex, evolving frameworks. Solutions include developing clear guidelines, fostering regulatory flexibility, promoting global harmonization, and ensuring patient engagement. This discussion highlighted the incredible potential and intricate challenges in the biotech and healthcare sectors. Together, we can drive innovation while addressing ethical and regulatory concerns to improve global health outcomes. 🌟 #Biotech #HealthcareInnovation #LongevityResearch #PrecisionMedicine #GeneEditing #ClinicalTrials #HealthTech #AI #Wearables WISE World Investors & Entrepreneurs Society Private Investment Forum Worldwide American Association for Precision Medicine (AAPM) #RegulatoryAffairs #PublicHealth #AI #News

41

2 commentaires